Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model

Shock

Volumn 9, Issue 4, 1998, Pages 274-281

  Darien, Benjamin J ^a,e   Fareed, Jawed ^c   Centgraf, Kim S ^a   Hart, Arlene P ^a   MacWilliams, Peter S ^b   Clayton, Murray K ^b   Wolf, Helmut ^d   Kruse Elliott, Kris T ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d Novartis Pharma GMBH Med Department   (Germany)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; LIPOPOLYSACCHARIDE; LOW MOLECULAR WEIGHT HEPARIN; PEROXIDASE; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BLOOD; BLOOD PRESSURE; CELL ADHESION; DRUG EFFECT; ENDOTOXEMIA; ESCHERICHIA COLI; HEMODYNAMICS; HEMOSTASIS; INJURY; LEUKOCYTE COUNT; LUNG; LUNG CIRCULATION; METABOLISM; NEUTROPHIL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SWINE; THROMBOCYTE; VASCULAR RESISTANCE;

ANIMALS; BLOOD PLATELETS; BLOOD PRESSURE; CELL ADHESION; ENDOTOXEMIA; ENDOTOXINS; ESCHERICHIA COLI; HEMODYNAMIC PROCESSES; HEMOSTASIS; HEPARIN, LOW-MOLECULAR-WEIGHT; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; LUNG; NEUTROPHILS; PEROXIDASE; PULMONARY CIRCULATION; SWINE; THROMBOXANE B2; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR RESISTANCE;

EID: 0032042304     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199804000-00007     Document Type: Article

References (44)

1. Frikkr MJ, Lynch K, Wilson RS, Rie MA, Zapol WM: The adult respiratory distress syndrome: Aetiology, progression and survival. In Artigas A, Artigus A, Lemaire F, Suter PM, Zapol WM (eds): Adult Respiratory Distress Syndrome. New York: Churchill Livingstone, 1992, pp 3-15.
2. Hasegawa N, Husari AW, Hart WT, Raffin TA: Role of coagulation system in ARDS. Chest 105:268-277, 1994.
3. Tomashefski JF Jr: Pulmonary pathology of adult respiratory distress syndrome. Clin Chest Med 11:593-619, 1990.
4. Meduri GU, Headley S, Kohler G, et al: Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Chest 107:1062-1073, 1995.
5. Sakamaki F, Ishizaka A, Handa M, et al: Soluble form of P-selectin in plasma is elevated in acute lung injury. Am J Respir Crit Care Med 151:1821-1826, 1995.
6. Sabharwal AK, Bajaj SP, Ameri A, et al: Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. Am J Respir Crit Care Med 151:758-767, 1995.
7. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP: Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82:3253-3258, 1993.
8. Lantz M, Thysell H, Nilsson E, Olsson I: On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 88:2026-2031, 1991.
9. Tyrell DJ, Kilfeather S, Page CP: Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci 16:198-204, 1995.
10. Hocking DC, Ferro TJ, Johnson A: Dextran sulfate inhibits PMN-dependent hydrostatic pulmonary edema induced by tumor necrosis factor. J Appl Physiol 70:1121-1128, 1991.
11. Hocking DC, Ferro TJ, Johnson A: Dextran sulfate and heparin sulfate inhibit platelet activating factor-induced pulmonary edema. J Appl Physiol 72:179-185, 1992.
12. Triplett EA, Kruse-Elliott KT, Hart AP, et al: SK&F 86002, a dual cytokine, eicosanoid inhibitor, attenuates endotoxin induced cardiopulmonary dysfunction in the pig. Shock 6:357-364, 1996.
13. Darien BJ, Saban MRM, Hart AP, MacWilliams PS, Clayton MK, Kruse-Elliott KT: Morphometric analysis of oleic acid-induced permeability pulmonary edema: Correlation with gravimetric lung water. Shock 8:61-67, 1997.
14. Hoppensteadt DA, Haas S, Breddin HK, Fareed J: Modulation of laboratory parameters and therapeutic and prophylactic administration of Sandoparin. Semin Thromb Hemost 19:31-35, 1993.
15. Darien BJ, Stone WC, Hart AP, Schilly DR, Clayton MK: Systemic haemostatic alterations during no-flow ischaemia and reperfusion of the ascending colon in ponies. Comp Haematol Int 6:63-69, 1996.
16. Olson NC, Kruse-Elliott KT, Dodam JR: Systemic and pulmonary reactions in swine with endotoxemia and Gram-negative bacteremia. J Am Vet Med Assoc 200:1870-1883, 1992.
17. Kruse-Elliott KT, Albert DH, Summers JB, Carter GW, Zimmerman JJ, Grossman JE: Attenuation of endotoxin-induced pathophysiology by a new potent PAF receptor antagonist. Shock 5:265-273, 1996.
18. Itoh K, Nakao A, Kishimot W, Takagi H: Heparin effects on superoxide production by neutrophils. Eur Surg Res 27:184-188, 1995.
19. Bazzoni G, Nuñez AB, Mascellani G, Bianchini P, Dejana E, Maschio AD: Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions. J Lab Clin Med 121:268-275, 1993.
20. Meyer J, Cox CS, Herndon DN, et al: Heparin in experimental hyperdynamic sepsis. Crit Care Med 21:84-89, 1993.
21. Hiebert L: Dextran sulfates and heparin protect cultured endothelial cells from free radical injury. Thromb Haemost 69:642-648, 1993.
22. Léculier C, Couprie N, Adeleine P, Leitienne P, Francina A, Richard M: The effects of high molecular weight and low molecular weight heparins on superoxide production and degranulation by human polymorphonuclear leukocytes. Thromb Res 69:519-531, 1993.
23. Cadroy Y, Gaspin D, Lormeau JC, Boneu B, Sié P: Heparin reverses the procoagulant properties of stimulated endothelial cells. Thromb Haemost 75:190-195, 1996.
24. 2 activity and prostacyclin synthesis in patients undergoing cardiac surgery. J Clin Invest 95:1062-1070, 1995.
25. 2 production by cultured endothelial cells. Thromb Res 57:481-488, 1990.
26. Bannon PG, Kim MJ, Dean RT, Dawes J: Augmentation of vascular endothelial barrier function by heparin and low molecular weight heparin. Thromb Haemost 73:706-712, 1995.
27. Blajchman MA, Young E, Ofosu FA: Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Ann NY Acad Sci 556:245-254, 1989.
28. Landolfi R, De Candia E, Rocca B, et al: Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosynthesis "in vivo." Thromb Haemost 72:942-946, 1994.
29. Hoffman H, Siebeck M, Spannagl M, et al: Effect of recombinant hirudin, a specific inhibitor of thrombin, on endotoxin-induced intravascular coagulation and acute lung injury in pigs. Am Rev Respir Dis 142:782-788, 1990.
30. Lum H, Anderson TT, Fenton II JW, Malik AB: Thrombin receptor activation peptide induces pulmonary vasoconstriction. Am J Physiol 266(Cell Physiol 35):C448-C454, 1994.
31. Horgan MJ, Fenton JW, Malik AB: α-Thrombin-induced pulmonary vasoconstriction. J Appl Physiol 63:1993-2000, 1987.
32. Waypa GB, Vincent PA, Morton CA, Minnear FL: Thrombin increases fluid influx in isolated rat lungs by a hemodynamic and not a permeability mechanism. J Appl Physiol 80:1197-1204, 1996.
33. Upchurch GR, Welch GN, Freedman JE, et al: High-dose heparin decreases nitric oxide production by cultured bovine endothelial cells. Circulation 95:2115-2121, 1997.
34. Yee J, Christou NV: The local role of tumor necrosis factor α in the mediation of neutrophil function at sites of inflammation. Arch Surg 129:1249-1255, 1994.
35. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-α in vitro and in vivo. Proc Natl Acad Sci USA 89:4845-4849, 1992.
36. Hibbs JJ, Taintor RR, Vavrin Z, Rachlin EM: Nitric oxide: A cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 157:87-94, 1988.
37. Spinas GA, Keller U, Brockhaus M: Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxemia. J Clin Invest 90:533-536, 1992.
38. Tartaglia, LA, Rothe M, Hu YF, Goeddel DV: Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor. Cell 73:213-216, 1993.
39. Redl H, Schlag G, Adolf GR, Natmessnig B, Davies J: Tumor necrosis factor (TNF)-dependent shedding of the p55 TNF receptor in a baboon model of bacteremia. Infect Immun 63:297-300, 1995.
40. Zimmerman BJ, Paulson JC, Arrhenius TS, Gaeta FCA, Granger DN: Thrombin receptor peptide-mediated leukocyte rolling in rat mesenteric venules: Roles of P-selectin and sialyl Lewis X. Am J Physiol 267(Heart Circ Physiol 36):H1049-H1053, 1994.
41. Lorant DE, McEver RP, McIntyre TM, Moore KL, Prescott SM: Activation of polymorphonuclear leukocytes reduces their adhesion to P-selectin and causes redistribution of ligands for P-selectin. J Clin Invest 96:171-182, 1995.
42. Lorant DE, Topham MK, Whatley RE, et al: Inflammatory role of P-selectin. J Clin Invest 92:559-570, 1993.
43. Harrison N, Granger DN: Mechanisms underlying enhanced capillary filtration induced by platelet activating factor. Am J Physiol 270(Heart Circ Physiol 39):H127-H133, 1996.
44. Chen C-R, Voelkel NF, Chang S-W: Platelet-activating factor potentiates Protamine-induced lung edema: Role of eicosanoids. J Respir Crit Care Med 149:34-40, 1994.